Eikon Therapeutics

CA - Millbrae

Biotechnology1 H-1B visas (FY2023)

Website LinkedIn Careers Page

Focus: Single Particle Tracking

Eikon Therapeutics is a life sciences company focused on Single Particle Tracking.

OncologyOphthalmologyNeurologyGene Therapy

Open Jobs

Pipeline & Clinical Trials

BDB001

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT03486301BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Phase 1

BDB018

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT04840394Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Phase 1

BDB001

Tumor, Solid

Phase 1

Clinical Trials (1)

NCT04196530BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Phase 1

EIK1004-001

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT06907043A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Phase 1/2

EIK1005

Advanced Solid Tumors

Phase 1/2

Clinical Trials (1)

NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Phase 1/2

IMP1734

Advanced Solid Tumor

Phase 1/2

Clinical Trials (1)

NCT06253130A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Phase 1/2

BDB001

Tumor, Solid

Phase 2

Clinical Trials (1)

NCT04819373BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

Phase 2

Association atezolizumab + BDB001 + RT

Solid Tumor, Adult

Phase 2

Clinical Trials (1)

NCT03915678Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Phase 2

EIK1001

NSCLC

Phase 2

Clinical Trials (1)

NCT06246110A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2

EIK1001

Non Small Cell Lung Cancer (Squamous or Non Squamous)

Phase 2/3

Clinical Trials (1)

NCT07365319A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Phase 2/3

EIK1001

Advanced Melanoma

Phase 2/3

Clinical Trials (1)

NCT06697301Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Phase 2/3

Open Jobs (30)

Eikon Therapeutics

Pipeline & Clinical Trials

Open Jobs (30)

Intern, Research Biology (Oncology)

Associate Director, Clinical Pharmacology

Associate Director, CMC Drug Product

Senior Medical Writer I

Senior Manager, Clinical Data Management (Contractor)

Senior Engineer, Data Informatics

Director, Regulatory Affairs

Senior Director, SEC Reporting & SOX

Stock Administration Senior Manager

Senior Director, Information Security

Senior Electrical Engineer

Senior Director, Procurement, Supply Chain

Senior Director, Intellectual Property (IP)

Senior Director, Clinical Research - Oncology

Senior Counsel, Corporate & Securities

Eikon G&A Talent Community

Eikon Research Talent Community

Lab Data Manager

Senior Research Associate 2, Neuroscience

Executive Director, Clinical R&D (Translational Medicine and Companion Diagnostics)

Associate Director, Clinical Data Analytics and Reporting

Clinical Trial Manager, Oncology, Asia

Director, Site Engagement & Monitoring Excellence

Senior Director, Clinical Research

Associate Director, Clinical Study Management

Hiring Trend

Visa Sponsorship